Riskpilot← Back to searchSign inGet full accessHilding Life Science AB
ABActiveOrg 5568101199Solnavägen 106Business and other management consultancy activities · NACE 7020Est. 20100 employees
Revenue 2025
—
EBITDA margin
—
-178% vs 2024
Equity ratio
85.4%
Financial strength
Net profit 2025
SEK -2K
-180% vs 2024
| Revenue | — | — |
| EBITDA | SEK -2K | -178% |
| Net profit | SEK -2K | -180% |
| Total assets | SEK 36K | -6% |
| Equity | SEK 31K | -7% |
| Employees | 0 | — |
Legal name
Hilding Life Science AB
Org number
5568101199
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
1 juni 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet ska vara management- och organisationskonsulting, kapitalförvaltning samt eventarrangemang inom branscher såsom läkemedel, medicinteknik samt bioteknik samt därmed förenlig verksamhet.
Address
Solnavägen 106
Email
fredrik.hilding@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −20 | −2 | −2 | 3 | −2 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −20 | −2 | −2 | 3 | −2 |
| Net financials | — | −0 | — | −0 | −0 |
| Profit before tax | −20 | −2 | −2 | 3 | −2 |
| Tax | −0 | — | — | — | — |
| Net profit | −20 | −2 | −2 | 3 | −2 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 44 | 42 | 40 | 39 | 36 |
| Equity | −16 | 32 | 30 | 33 | 31 |
| Long-term debt | 55 | 5 | 5 | 5 | 5 |
| Short-term debt | 6 | 5 | 5 | 1 | 0 |
| Total debt | 61 | 10 | 10 | 5 | 5 |
EBITDA margin
-220000.0%
This company
15.8%
Market median
-1392505% vs market
20212025
Equity ratio
85.4%
This company
38.2%
Market median
+124% vs market
20212025
Return on equity
-7.2%
This company
18.4%
Market median
-139% vs market
20212025
Net profit margin
-223700.0%
This company
8.1%
Market median
-2761828% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Hilding Life Science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Fredrik Hilding | Board of Directors | 0 companies |
| Lars Robert Hilding | Deputy Board Member | 0 companies |